Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer
Globe Newswire•01/09/2026•08:30 ET
0
Whiz Insights
Dr. Charlton brings over 15 years of rare disease and pediatric drug development experience including CMO and clinical development roles
Appointment further strengthens clinical leadership and execution capabilities ahead of planned SOTERIA Phase 2 initiation in Q4 2026
Get started
Create a free account to read the full story.